

Market Opportunity

MacroArray Technologies Inc., LLC is poised for near term success with its unique platform of technologies that provides access to the large and growing cancer diagnostic and therapeutic markets that is estimated to be \$20 billion per year. Initial focus is being placed on developing the company's urine-based diagnostic test for prostate cancer.

Investment Highlights

- A validated and proprietary gene discovery technology.
- Developing accurate and cost effective diagnostic tests that could be used to measure therapeutic efficacy.
- Diagnostic oncology market focus.
- Near term revenue opportunity with PCADM-1 urine test.
- Multiple Product opportunities: PCADM-1, PCADM-2, HGPIN, CAM-1 & DNA ZYM-1.
- Experienced management & scientific team.
- Broad based IP protection.

Executive Management

Michael J. Wassil, CEO

Mark Stearns, Ph.D., President and CSO

Youji Yu, Ph.D., Vice President Research

Min Wang, Ph.D., Director of Research

For more information, contact:

Michael J. Wassil, CEO

MacroArray Technologies, LLC.

Phone 610.764.3066

Fax 215.762.7880

Email mwassil@macroarraytech.com

www.macroarraytech.com

Corporate Overview

MacroArray Technology, LLC is an early stage biotechnology company formed to capitalize on the growing need for more efficient and effective technology to rapidly identify and develop:

- Novel diagnostic markers for the early detection and staging of cancer and other diseases.
- Novel therapeutics linked to the diagnostic markers for a variety of cancers.

Core Technologies include:

- Proteomics platform for novel marker discovery.
- DNA-protein binding technology.
- Proprietary methods for cloning/identification of genes/proteins.
- Proprietary immunoassays for tissue/fluid markers.
- Linking diagnostic markers to therapeutics.
- 'DNA ZYM' (Ribozyme-like) therapeutic agents for the treatment of cancer.
- Broad patent application covering discovery process, diagnostics, and therapeutics applications.

Prostate Cancer Programs

MacroArray Technology will initially focus its efforts on developing prostate cancer diagnostic products. The primary objective is to obtain FDA approval to commercialize PCADM-1 as a clinical diagnostic test for prostate cancer.

PCADM-1

A urine-based diagnostic test for prostate cancer. This test is designed to supplant and potentially replace the PSA blood test currently in use. The advantages of the PCADM-1 test are that it is non-invasive, easily administered, safe and extremely cost effective for the diagnosis of prostate cancer. The availability of a simple yet reliable urine based test would facilitate periodic testing of patients to more accurately assess their medical condition and status of disease progression, remission or recurrence.

Standard PSA Test vs. PCADM-1

PSA

Invasive - blood test

Poor sensitivity/specificity, with ~30% false positives and false negatives, requiring repeated testing

Low patient compliance, <20%

No link to a specific therapeutic

PCADM-1

Non-invasive - urine based

Significantly improved sensitivity/specificity at >80%

Ease of use with high patient compliance

A diagnostic marker linked to a therapeutic agent

Scientific Advisors

Jeffrey Freed, M.D., Colon Surgeon
Albert Einstein Hospital, N.Y.

James England, M.D., Ph.D.,
Chairman of Pathology
Drexel University College of Medicine

Len Gomella, MD
Chairman of Urology
Thomas Jefferson University

Urology Centers/Collaborators

Graduate Hospital
Fernando Garcia, M.D.
Chairman of Pathology

University of Pittsburgh
Jeffrey Gingrich, M.D.
Urologist

University of Colorado Medical Center
David Crawford, M.D.
Director of Clinical Cancer Division

Mistelbach, Austria
Paul Lunglmayr, M.D.
Director of Weinviertel Klinikum and
Chairman of Urology
Gerhard Lunglmayr
Weinviertel Klinikum

Investors

- NIH-NCI (University grants thru 2009)
- Drexel University College of Medicine
- LORE
- Ben Franklin Technology Partners
- BioAdvance
- Innovation Philadelphia

Intellectual Property

MacroArray has licensed intellectual property from Drexel University College of Medicine (DUCOM), formerly MCP Hahnemann University. The license provides exclusive rights to the proteomics discovery technology and discoveries made for diagnostic and therapeutic applications.

Pipeline Products

Our early development stage products include HGPIN-1, a urine-based marker for pre-malignant prostate cancer; CAM-1, a serum-based marker for colon cancer; PCADM-2, a serum-based marker for prostate cancer; and DNA-ZYM-1, a pre-clinical therapeutic for prostate cancer.

HGPIN-1 Marker (High Grade Preneoplastic Intraepithelial Neoplasia)

HGPIN is believed to be a precursor of prostate cancer; patients with HGPIN may go on to develop prostate cancer. Currently, biopsy is the only method for detection of HGPIN lesions, although a biopsy is most often inconclusive. Development of a urine assay for HGPIN will enable early diagnosis and treatment of cancer to prevent disease progression.

MacroArray Technologies has identified a tissue and urine diagnostic marker, termed HGPIN-1, which detects HGPIN in nearly 100% of the biopsy positive patients. Approximately 130,000 new cases of HGPIN are diagnosed each year.

CAM-1

Current diagnosis of colon cancer depends largely upon a 'stool-DNA test' or expensive and invasive colonoscopy examinations. CAM-1 is only found in the serum of colon cancer tissues, not normal tissues, and is intended to replace stool-based and DNA based tests currently in use.

PCADM-2

A serum-based marker for prostate cancer. This program is in the research phase and additional studies will be conducted to validate PCADM-2 as a potential serum marker for prostate cancer.

DNA ZYM-1P

In the therapeutic area, the Company has developed a "DNA ZYM-1P" oligonucleotide technology, which targets the prostate cancer tumor gene associated with PCADM-1. Pre-clinical animal model studies have demonstrated that the "DNA ZYM-1P" therapy in localized delivery leads to rapid tumor regression and eradication in ~ 90% of the tumors (n=55 animals). A second animal study using systemic delivery resulted in ~85%-100% tumor eradication and blockade of metastatic growth.